Effect of spironolactone on human brown fat in patients with primary aldosteronism

Not Applicable

• Conditions: Primary aldosteronism; Obesity; Diet and Nutrition - Obesity; Metabolic and Endocrine - Other metabolic disorders

• Registration Number: ACTRN12614001116617
• Lead Sponsor: Professor Ken Ho

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-10-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Subjects with primary aldosteronism who will be treated with at least 4 weeks of spironolactone

Exclusion Criteria

Pregnancy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Brown fat volume changes on 18FDG-PET-CT scan[before and at least 4 weeks after treatment with spironolactone (but no more than 8 weeks after treatment commencement)];Brown fat activity changes on 18-FDG-PET-CT scan[before and at least 4 weeks after treatment with sprionolactone (but no more than 8 weeks after treatment commencement)]

Secondary Outcome Measures

Name	Time	Method
changes in resting energy expenditure using indirect calorimetry[before and at least 4 weeks after treatment with spironolactone (but no more than 8 weeks after treatment commencement)];changes in diet-induced thermogenesis using indirect calorimetry[before and at least 4 weeks after treatment with spironolactone (but no more than 8 weeks after treatment commencement)]